• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?

作者信息

Benitez Jose Carlos, Remon Jordi, Besse Benjamin

机构信息

Gustave Roussy, Department of Cancer Medicine, Villejuif, France.

Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.

出版信息

Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S464-S467. doi: 10.21037/tlcr.2019.12.26.

DOI:10.21037/tlcr.2019.12.26
PMID:32038939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6987362/
Abstract
摘要

相似文献

1
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?CheckMate 153研究：年龄和体能状态与免疫检查点抑制剂疗效相关吗？
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S464-S467. doi: 10.21037/tlcr.2019.12.26.
2
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.血清白细胞介素-6 和 C 反应蛋白与接受免疫检查点抑制治疗的黑色素瘤患者的生存相关。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000842. Epub 2020 Jun 23.
3
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.免疫检查点抑制剂治疗的生存异质性及其对生存外推的影响：晚期黑色素瘤的案例研究
MDM Policy Pract. 2022 Mar 26;7(1):23814683221089659. doi: 10.1177/23814683221089659. eCollection 2022 Jan-Jun.
4
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial.纳武利尤单抗用于CheckMate-141试验排除的原发部位和组织学亚型的头颈癌患者的疗效。
Cancer Manag Res. 2020 Jun 3;12:4161-4168. doi: 10.2147/CMAR.S249393. eCollection 2020.
5
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.使用互补统计方法评估长期治疗益处：III期KEYNOTE-045和CheckMate-214免疫检查点抑制剂试验的计算机模拟分析
Eur Urol. 2024 Mar;85(3):293-300. doi: 10.1016/j.eururo.2023.02.011. Epub 2023 Feb 26.
6
Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.日本食管癌肿瘤学组对食管癌免疫治疗发展的现状观点。
Jpn J Clin Oncol. 2022 Oct 6;52(10):1089-1096. doi: 10.1093/jjco/hyac138.
7
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.纳武利尤单抗对比多西他赛用于治疗既往接受过治疗的晚期非小细胞肺癌（CheckMate 017 和 CheckMate 057）：3 年更新结果及肝转移患者的结局。
Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.
8
Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.基于套索逻辑回归的新型特定突变分类器的开发与验证，用于预测肾细胞癌免疫检查点抑制剂治疗的总生存期
Transl Androl Urol. 2023 Mar 31;12(3):406-424. doi: 10.21037/tau-23-21.
9
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.免疫检查点抑制剂治疗晚期黑色素瘤患者的无治疗生存随访延长。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003743.
10
Cost-effectiveness of nivolumab in advanced melanoma: a drug review.尼伏单抗治疗晚期黑色素瘤的成本效益：药物评价。
Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):13-28. doi: 10.1080/14737167.2021.1845144. Epub 2020 Dec 6.

本文引用的文献

1
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.TAIL 研究的主要结果：一项在先前接受过治疗的晚期非小细胞肺癌的多种族患者中进行的阿替利珠单抗单药治疗的全球性单臂安全性研究。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001865.
2
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.意大利非小细胞肺癌纳武利尤单抗扩展使用项目总体人群和关键亚组的真实世界研究结果。
Eur J Cancer. 2019 Dec;123:72-80. doi: 10.1016/j.ejca.2019.09.011. Epub 2019 Oct 28.
3
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.免疫疗法在老年非小细胞肺癌患者中的疗效和安全性。
Lung Cancer. 2019 Nov;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. Epub 2019 Sep 10.
4
Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status.纳武单抗治疗晚期非小细胞肺癌且体能状态较差患者的疗效与安全性
J Cancer. 2019 May 19;10(10):2139-2144. doi: 10.7150/jca.31217. eCollection 2019.
5
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.帕博利珠单抗治疗晚期非小细胞肺癌：日常临床实践中的疗效和安全性。
Lung Cancer. 2019 Jul;133:110-116. doi: 10.1016/j.lungcan.2019.05.005. Epub 2019 May 18.
6
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).纳武利尤单抗治疗晚期非小细胞肺癌患者的安全性、疗效以及患者报告的健康相关生活质量和症状负担，包括 70 岁或以上或体能状态不佳的患者（CheckMate 153）。
J Thorac Oncol. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20.
7
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.晚期非小细胞肺癌：2018 年胸部肿瘤学进展。
J Thorac Oncol. 2019 Jul;14(7):1134-1155. doi: 10.1016/j.jtho.2019.03.022. Epub 2019 Apr 16.
8
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.美国监管批准后一年接受程序性死亡蛋白 1 抑制剂治疗的转移性非小细胞肺癌患者的真实世界结局。
Oncologist. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27.
9
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).纳武利尤单抗对比多西他赛用于既往接受过治疗的晚期非小细胞肺癌患者：两项随机、开放标签、III期试验（CheckMate 017和CheckMate 057）的两年结果
J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.
10
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?免疫衰老与非小细胞肺癌患者的免疫检查点抑制剂：年龄真的重要吗？
Cancer Treat Rev. 2017 Nov;60:60-68. doi: 10.1016/j.ctrv.2017.08.003. Epub 2017 Aug 24.